Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05241275 · ClinicalTrials.gov registry record · Phase 2
Xenon MRI and Progressive ILD
A Phase 2 study of Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis, sponsored by Duke University.
- Active
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05241275: Active Phase 2 study of Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis, sponsored by Duke University.
NCT05241275 is a Phase 2 study of Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis that is active but no longer recruiting, run by Duke University. The registered enrollment target is 60 participants, below the 750-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05241275, a Phase 2 study of Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis, is active but no longer recruiting, sponsored by Duke University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The XENON ILD study is a single arm, un-blinded study at Duke University enrolling patients with non-idiopathic pulmonary fibrosis (IPF) progressive fibrosis (PF) interstitial lung disease (ILD). Patients who meet criteria for ILD-progression (defined below in inclusion/exclusion criteria) will be consented prior to the initiation of anti-fibrotic therapy. Subjects will undergo an approximately hour long comprehensive MRI protocol, including administration of multiple doses of hyperpolarized 129Xe. The subjects will have this initial study prior to initiation of anti-fibrotic therapies and repeat MRI studies at 3, 6 and 12 months following the initiation of therapy. If subjects do not decide to initiate anti-fibrotic therapy per discussion with their physician, then the 3, 6 and 12 months repeat studies will initiate based on time after enrollment.
Primary Outcome
The outcome will assess changes in 129Xe MRI barrier uptake 3 months after nintedanib initiation.
Conditions Studied
Interventions
- DRUG Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment
Study Locations (1)
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-07-19 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 2 |
What the registry record for NCT05241275 still lists
NCT05241275 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 750-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment is the first listed.
NCT05241275 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05241275 about?
NCT05241275 is a clinical study titled "Xenon MRI and Progressive ILD". The XENON ILD study is a single arm, un-blinded study at Duke University enrolling patients with non-idiopathic pulmonary fibrosis (IPF) progressive fibrosis (PF) interstitial lung disease (ILD). Patients who meet criteria for ILD-progression (defined below in inclusion/exclusion criteria) will be c...
What is the current status of trial NCT05241275?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2022-07-19. Estimated completion is 2026-08-31.
What conditions does trial NCT05241275 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis.
What interventions are being tested in trial NCT05241275?
The interventions under investigation include: Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment (DRUG).
Who is sponsoring clinical trial NCT05241275?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05241275 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05241275's enrollment target sits among peer trials
60 27th of 51 higher than 24 of 51 other Idiopathic Pulmonary Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
RECRUITING · Phase 2
-
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
RECRUITING · Phase 2
-
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
RECRUITING · Phase 2
-
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI